Clinical Trials Logo

Hemorrhagic Disorders clinical trials

View clinical trials related to Hemorrhagic Disorders.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06290440 Not yet recruiting - Clinical trials for Anticoagulants; Circulating, Hemorrhagic Disorder

MEdication Counselling Models for Outpatient oRal antIcoaguLation

MEMORIAL
Start date: June 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to investigate whether telepharmacy-led counselling can improve medication adherence, knowledge, and hospitalisation/mortality compared with pharmacist-led counselling in adult outpatients taking oral anticoagulants.

NCT ID: NCT06271252 Not yet recruiting - Clinical trials for Cardiovascular Diseases

A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study

Start date: April 15, 2024
Phase: Phase 1
Study type: Interventional

The is a first clinical study for Oricell Therapeutics Inc. in the United States to evaluate the safety, PK, PD and preliminary efficacy of our anti-GPRC5D cell product (OriCAR-017) in subjects with relapsed/refractory multiple myeloma. RIGEL Study

NCT ID: NCT05916469 Not yet recruiting - Clinical trials for Heavy Menstrual Bleeding

Heavy Menstrual Bleeding Progestin Treatment in Bleeding Disorders Study

HMB-BD
Start date: July 2024
Phase:
Study type: Observational [Patient Registry]

The goal of this multicenter prospective observational study and registry of U.S. adolescents and young adults with heritable bleeding disorders is to determine the bleeding outcomes, satisfaction, hemostatic parameter changes, and patient reported quality of life after 6 months of use of either of two commonly used hormonal treatments for menstrual suppression - levonorgestrel intrauterine device (LNG-IUD) and norethindrone acetate (NETA). Under this application we will compare the two treatments and compare outcomes after LNG-IUD treatment results to a control group without a bleeding disorder, with the goal of determining the benefits and expected outcomes of these treatment options for this population.

NCT ID: NCT05654766 Not yet recruiting - Acute Leukemia Clinical Trials

Assesment of the Functional Activity of Platelets for the Differential Diagnosis of Thrombocytopathies

Start date: January 2, 2023
Phase:
Study type: Observational

The purpose of this study is to develop a highly sensitive method for assessing the functional activity of platelets for use in the differential diagnosis of thrombocytopenia and platelet defects.

NCT ID: NCT03174093 Not yet recruiting - Atrial Fibrillation Clinical Trials

Mhealth Application for anTicoagulation Care in Atrial Fibrillation

MATCh AFib
Start date: June 2017
Phase: N/A
Study type: Interventional

This study will assess the benefits of using a mobile health application designed for shared decision aid in anticoagulation therapy in patients with Atrial Fibrillation (AF). The aim is to improve their treatment adherence and time in therapeutic International Normalized Ratio (INR) range. The results of this study have the potential to lead to a sustainable and resource-efficient strategy for better prevent thromboembolic events in patients with atrial fibrillation.

NCT ID: NCT02969746 Not yet recruiting - Clinical trials for Anticoagulants; Circulating, Hemorrhagic Disorder

Activates Charcoal for Patients Undergoing Invasive Procedure Delayed Due to Direct Oral Anticoagulants

CACAOD
Start date: September 2017
Phase: Phase 4
Study type: Interventional

This is a prospective, multicentric, randomized, open labeled superiority trial This study aims to evaluate the efficacy of oral activated charcoal for improving elimination of direct oral anticoagulants ( Rivaroxaban, Apixaban) in case of an unscheduled invasive procedure delayed to this anticoagulant treatment. The primary outcome is the anticoagulant's half life. Plasma concentration will be measured by liquid chromatography-mass spectrometry for the main analysis (pharmacokinetic). A total of 140 patients will randomly be assigned to the charcoal or control group, stratified according to their anticoagulant drug.